BR112019010349A2 - Anticorpos anti-fixa, anti-fxz e antifxa, molécula biespecífica, ácido nulceico, composiçãofarmacêutica e uso dos anteriores - Google Patents
Anticorpos anti-fixa, anti-fxz e antifxa, molécula biespecífica, ácido nulceico, composiçãofarmacêutica e uso dos anterioresInfo
- Publication number
- BR112019010349A2 BR112019010349A2 BR112019010349A BR112019010349A BR112019010349A2 BR 112019010349 A2 BR112019010349 A2 BR 112019010349A2 BR 112019010349 A BR112019010349 A BR 112019010349A BR 112019010349 A BR112019010349 A BR 112019010349A BR 112019010349 A2 BR112019010349 A2 BR 112019010349A2
- Authority
- BR
- Brazil
- Prior art keywords
- fxz
- antibodies
- fixed
- antigen
- factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
a presente invenção refere-se a anticorpos que se ligam seletivamente a formas específicas de fatores de coagulação, em particular anticorpos que se ligam especificamente ao fator ix ativado (fixa), em que o anticorpo anti-fixa ou uma porção de ligação a antígeno do mesmo se liga preferencialmente ao fixa na presença de fixa e zimogênio do fator ix (fixz), e anticorpos que se ligam especificamente ao zimogênio do fator x (fxz), em que o anticorpo anti-fxz ou uma porção de ligação a antígeno do mesmo se liga preferencialmente ao fxz na presença de fxz e fator x ativado (fxa). também são fornecidas moléculas biespecíficas (por exemplo, anticorpos) que compreendem, por exemplo, um anticorpo anti-fixa ou uma porção de ligação a antígeno do mesmo e/ou um anticorpo anti-fxz ou porção de ligação a antígeno do mesmo. a invenção também fornece composições que codificam os anticorpos descritos e moléculas biespecíficas, vetores, células, composições farmacêuticas e diagnósticas, kits, métodos de produção, métodos de uso e imunoconjugados.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662425921P | 2016-11-23 | 2016-11-23 | |
US201762452809P | 2017-01-31 | 2017-01-31 | |
US201762529805P | 2017-07-07 | 2017-07-07 | |
US201762587284P | 2017-11-16 | 2017-11-16 | |
PCT/US2017/063135 WO2018098363A2 (en) | 2016-11-23 | 2017-11-22 | Bispecific antibodies binding to coagulation factor ix and coagulation factor x |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019010349A2 true BR112019010349A2 (pt) | 2019-10-08 |
Family
ID=60766147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019010349A BR112019010349A2 (pt) | 2016-11-23 | 2017-11-22 | Anticorpos anti-fixa, anti-fxz e antifxa, molécula biespecífica, ácido nulceico, composiçãofarmacêutica e uso dos anteriores |
Country Status (21)
Country | Link |
---|---|
US (1) | US20230192896A1 (pt) |
EP (1) | EP3545002A2 (pt) |
JP (2) | JP7227146B2 (pt) |
KR (1) | KR20190080949A (pt) |
CN (1) | CN110662770A (pt) |
AU (1) | AU2017363309A1 (pt) |
BR (1) | BR112019010349A2 (pt) |
CA (1) | CA3044574A1 (pt) |
CL (1) | CL2019001372A1 (pt) |
CO (1) | CO2019006500A2 (pt) |
CR (1) | CR20190297A (pt) |
DO (1) | DOP2019000127A (pt) |
EC (1) | ECSP19044484A (pt) |
IL (1) | IL266749A (pt) |
MA (1) | MA46893A (pt) |
MX (1) | MX2019005772A (pt) |
PE (1) | PE20200012A1 (pt) |
PH (1) | PH12019501126A1 (pt) |
TN (1) | TN2019000164A1 (pt) |
TW (1) | TW201819417A (pt) |
WO (1) | WO2018098363A2 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
MA40861A (fr) * | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
JP7437301B2 (ja) | 2017-08-25 | 2024-02-22 | ファイヴ プライム セラピューティクス インク | B7-h4抗体及びその使用方法 |
US11787874B2 (en) | 2017-11-15 | 2023-10-17 | Novo Nordisk A/S | Factor X binders enhancing FX activation |
EA202091810A1 (ru) | 2018-03-02 | 2021-01-29 | Файв Прайм Терапьютикс, Инк. | Антитела к b7-h4 и способы их применения |
US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
CN117343188A (zh) * | 2018-08-01 | 2024-01-05 | 诺和诺德股份有限公司 | 改进的促凝血抗体 |
WO2020051275A1 (en) * | 2018-09-05 | 2020-03-12 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies against endotrophin and the use thereof |
WO2020114615A1 (en) * | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Bispecific antibodies binding factor ixa and factor x |
WO2020115283A1 (en) * | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Bispecific antibodies binding factor ixa and factor x |
TW202039583A (zh) * | 2018-12-07 | 2020-11-01 | 瑞士商巴克斯歐塔有限公司 | 結合因子IXa及因子X的蛋白分子 |
WO2020114614A1 (en) * | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Proteinaceous molecules binding factor ixa and factor x |
CA3121420A1 (en) * | 2018-12-13 | 2020-06-18 | Surface Oncology, Inc. | Anti-il-27 antibodies and uses thereof |
CA3123177A1 (en) | 2018-12-21 | 2020-06-25 | Kymab Limited | Fixaxfx bispecific antibody with common light chain |
WO2021152066A1 (en) * | 2020-01-30 | 2021-08-05 | Novo Nordisk A/S | Bispecific factor viii mimetic antibodies |
JP2023106635A (ja) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法 |
WO2021231237A2 (en) * | 2020-05-11 | 2021-11-18 | Augmenta Bioworks, Inc. | Antibodies for sars-cov-2 and uses thereof |
AU2021286655A1 (en) * | 2020-06-12 | 2023-01-05 | Nkarta, Inc. | Genetically modified natural killer cells for CD70-directed cancer immunotherapy |
CN117440973A (zh) * | 2021-04-09 | 2024-01-23 | 索伦托药业有限公司 | 与ror1结合的抗原结合蛋白 |
WO2023111018A1 (en) * | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Antibodies against coagulation factor x and uses thereof |
WO2023219922A1 (en) * | 2022-05-12 | 2023-11-16 | Merck Sharp & Dohme Llc | Anti-integrin antibodies and uses thereof |
CN116589588B (zh) * | 2023-04-14 | 2023-12-22 | 北京基科晟斯医药科技有限公司 | 结合凝血因子x的抗体 |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
CH0229046H1 (de) | 1985-03-30 | 1998-07-15 | Stuart Alan Kauffman | Method for obtaining dna, rna, peptides, polypeptinique. des or proteins by means of a dna recombinant tech |
US4770999A (en) | 1985-04-22 | 1988-09-13 | Genetics Institute, Inc. | High yield production of active Factor IX |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
CA2057923A1 (en) | 1989-05-16 | 1990-11-17 | William D. Huse | Co-expression of heteromeric receptors |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
WO1993022332A2 (en) | 1992-04-24 | 1993-11-11 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
WO1997008320A1 (en) | 1995-08-18 | 1997-03-06 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
US6706484B1 (en) | 1995-08-18 | 2004-03-16 | Morphosys Ag | Protein/(poly)peptide libraries |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
EP1724282B1 (en) | 1997-05-21 | 2013-05-15 | Merck Patent GmbH | Method for the production of non-immunogenic proteins |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
ES2353268T3 (es) | 1999-07-02 | 2011-02-28 | Morphosys Ag | Generacion de elementos de union especifica que se unen a (poli)peptidos codificados por fragmentos de adn genomico o est. |
AT411997B (de) * | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
EP1252192B1 (en) | 2000-02-11 | 2006-08-16 | MERCK PATENT GmbH | Enhancing the circulating half-life of antibody-based fusion proteins |
NZ521540A (en) | 2000-04-11 | 2004-09-24 | Genentech Inc | Multivalent antibodies and uses therefor |
US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
CA2478169C (en) * | 2002-03-04 | 2013-04-16 | Imclone Systems Incorporated | Human antibodies specific to kdr and uses thereof |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
CA2495251C (en) | 2002-08-14 | 2018-03-06 | Macrogenics, Inc. | Fc.gamma.riib-specific antibodies and methods of use thereof |
DK2345671T3 (en) | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
AU2003286467B2 (en) | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
AU2003285878B2 (en) | 2002-11-07 | 2011-04-28 | Immunogen, Inc. | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス,インコーポレーテッド | 変異型Fc領域を含む抗体の同定および作製ならびにその利用法 |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
WO2005035753A1 (ja) * | 2003-10-10 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | 機能蛋白質を代替する二重特異性抗体 |
JP5490734B2 (ja) * | 2003-10-10 | 2014-05-14 | 中外製薬株式会社 | 機能蛋白質を代替する二種特異性抗体 |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
US20080089892A1 (en) | 2004-01-12 | 2008-04-17 | Eli Lilly And Co. | Fc Region Variants |
EP1725585A2 (en) | 2004-03-10 | 2006-11-29 | Lonza Ltd | Method for producing antibodies |
EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
DK1776384T3 (da) | 2004-08-04 | 2013-09-02 | Mentrik Biotech Llc | VARIANT-Fc-REGIONER |
US20080312425A1 (en) | 2004-08-30 | 2008-12-18 | Lonza Biologics Plc. | Ion Exchange Chromatography and Purification of Antibodies |
WO2006106905A1 (ja) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | 会合制御によるポリペプチド製造方法 |
JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー/エス | 二重特異性抗体の生産 |
ES2619943T3 (es) * | 2007-01-03 | 2017-06-27 | Morphotek, Inc. | Anticuerpos de alta afinidad que neutralizan la enterotoxina B estafilocócica |
US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
US7700734B2 (en) | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
BRPI0816785A2 (pt) | 2007-09-14 | 2017-05-02 | Adimab Inc | bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
EP2242762B1 (en) | 2008-01-18 | 2015-12-16 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibodies and antibody fragments by apatite chromatography |
JP5501439B2 (ja) | 2009-04-02 | 2014-05-21 | ロシュ グリクアート アクチェンゲゼルシャフト | 完全長抗体と単鎖Fabフラグメントとを含む多重特異的抗体 |
KR101456326B1 (ko) | 2009-04-07 | 2014-11-12 | 로슈 글리카트 아게 | 3가, 이중특이적 항체 |
JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
RU2570633C2 (ru) | 2009-05-27 | 2015-12-10 | Ф.Хоффманн-Ля Рош Аг | Три- или тетраспецифические антитела |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
CN104945509A (zh) | 2009-09-16 | 2015-09-30 | 弗·哈夫曼-拉罗切有限公司 | 包含卷曲螺旋和/或系链的蛋白质复合体及其用途 |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
RU2624027C2 (ru) | 2010-04-23 | 2017-06-30 | Дженентек, Инк. | Получение гетеромультимерных белков |
MX360336B (es) | 2010-07-16 | 2018-10-30 | Adimab Llc Star | Colecciones de anticuerpos. |
MY166429A (en) * | 2010-11-17 | 2018-06-26 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
MX359384B (es) | 2011-10-11 | 2018-09-25 | Genentech Inc | Conjunto mejorado de anticuerpos bisespecificos. |
BR112014019579A2 (pt) | 2012-02-10 | 2019-10-15 | Genentech, Inc | Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero |
EP3283099B1 (en) * | 2015-04-17 | 2022-03-02 | F. Hoffmann-La Roche AG | Combination therapy with coagulation factors and multispecific antibodies |
-
2017
- 2017-11-22 MX MX2019005772A patent/MX2019005772A/es unknown
- 2017-11-22 EP EP17817962.8A patent/EP3545002A2/en active Pending
- 2017-11-22 WO PCT/US2017/063135 patent/WO2018098363A2/en unknown
- 2017-11-22 PE PE2019001058A patent/PE20200012A1/es unknown
- 2017-11-22 TN TNP/2019/000164A patent/TN2019000164A1/en unknown
- 2017-11-22 JP JP2019547608A patent/JP7227146B2/ja active Active
- 2017-11-22 AU AU2017363309A patent/AU2017363309A1/en not_active Abandoned
- 2017-11-22 KR KR1020197017712A patent/KR20190080949A/ko not_active Application Discontinuation
- 2017-11-22 CN CN201780084392.6A patent/CN110662770A/zh active Pending
- 2017-11-22 CR CR20190297A patent/CR20190297A/es unknown
- 2017-11-22 CA CA3044574A patent/CA3044574A1/en not_active Abandoned
- 2017-11-22 US US16/462,878 patent/US20230192896A1/en active Pending
- 2017-11-22 BR BR112019010349A patent/BR112019010349A2/pt not_active Application Discontinuation
- 2017-11-22 MA MA046893A patent/MA46893A/fr unknown
- 2017-11-23 TW TW106140758A patent/TW201819417A/zh unknown
-
2019
- 2019-05-20 IL IL266749A patent/IL266749A/en unknown
- 2019-05-20 CL CL2019001372A patent/CL2019001372A1/es unknown
- 2019-05-21 DO DO2019000127A patent/DOP2019000127A/es unknown
- 2019-05-21 PH PH12019501126A patent/PH12019501126A1/en unknown
- 2019-06-20 CO CONC2019/0006500A patent/CO2019006500A2/es unknown
- 2019-06-21 EC ECSENADI201944484A patent/ECSP19044484A/es unknown
-
2023
- 2023-02-08 JP JP2023017261A patent/JP2023058589A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CR20190297A (es) | 2019-11-01 |
US20230192896A1 (en) | 2023-06-22 |
DOP2019000127A (es) | 2019-10-15 |
CO2019006500A2 (es) | 2019-06-28 |
ECSP19044484A (es) | 2019-08-30 |
KR20190080949A (ko) | 2019-07-08 |
WO2018098363A3 (en) | 2018-09-20 |
CL2019001372A1 (es) | 2019-11-04 |
PE20200012A1 (es) | 2020-01-06 |
TN2019000164A1 (en) | 2020-10-05 |
MA46893A (fr) | 2019-10-02 |
AU2017363309A1 (en) | 2019-07-11 |
IL266749A (en) | 2019-07-31 |
JP7227146B2 (ja) | 2023-02-21 |
EP3545002A2 (en) | 2019-10-02 |
JP2023058589A (ja) | 2023-04-25 |
PH12019501126A1 (en) | 2019-08-19 |
JP2019535325A (ja) | 2019-12-12 |
CN110662770A (zh) | 2020-01-07 |
WO2018098363A2 (en) | 2018-05-31 |
CA3044574A1 (en) | 2018-05-31 |
MX2019005772A (es) | 2019-10-02 |
TW201819417A (zh) | 2018-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019010349A2 (pt) | Anticorpos anti-fixa, anti-fxz e antifxa, molécula biespecífica, ácido nulceico, composiçãofarmacêutica e uso dos anteriores | |
PE20170782A1 (es) | Anticuerpos frente a cd73 y usos de los mismos | |
CL2020003409A1 (es) | Moléculas de unión específicas para cd73 y métodos de fabricación de las mismas (divisional de la solicitud no. 201701154) | |
EA201891983A1 (ru) | Комбинированная терапия антителами к cd73 | |
BR112018000696A2 (pt) | ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit? | |
CO2018014325A2 (es) | Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso | |
BR112018001374A2 (pt) | construtos de anticorpo biespecíficos que se ligam a egfrviii e cd3 | |
BR112018001638A8 (pt) | construtos de anticorpo biespecífico que se ligam à mesotelina e cd3 | |
BR112018001530A2 (pt) | anticorpo biespecífico, polinucleotídeo, vetor, célula hospedeira, métodos para produzir o anticorpo biespecífico e de inibição do crescimento de células tumorais e composição farmacêutica | |
BR112018000475A2 (pt) | construtos de anticorpo biespecíficos que se ligam a dll3 e a cd3 | |
BR112014008382A2 (pt) | anticorpo especificamente ligando a epítope no domínio sema do c-met | |
BR112017014805A2 (pt) | anticorpos anti-cd3, anticorpos anti-cd123 e anticorpos biespecíficos que se ligam especificamente a cd3 e/ou cd123 | |
BR112018001531A2 (pt) | construtos de anticorpo para cd70 e cd3 | |
BR112018005573A2 (pt) | ?polipeptídeos de ligação a cd3? | |
CU20180024A7 (es) | Moléculas de unión a linfopoyetina estromal tímica (tslp), composiciones farmacéuticas que las contienen y método de producción de las mismas | |
BRPI0909044B8 (pt) | anticorpo que se liga especificamente ao csf-1r humano,composição farmacêutica e uso dos mesmos | |
BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
BR112016016916A8 (pt) | uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae) | |
BR112016012666A2 (pt) | conjugado, anticorpos, formulação farmacêutica e usos de conjugado | |
BR112017006598A2 (pt) | anticorpo de repetições antidipeptídeo derivado de ser humano (dprs) | |
BR112016017764A2 (pt) | anticorpo antidengue de amplo espectro | |
BR112015009954A2 (pt) | Uso de um anticorpo produzido contra um polipeptídeo de erfe, um polipeptídeo de erfe, uma molécula de ácido nucleico de erfe ou uma composição; e kit | |
BR112015029300A2 (pt) | Anticorpo biespecífico, composição farmacêutica compreendendo o mesmo, seus usos, usos de um anticorpo anti-ccl2, e um anticorpo anti-loxl2, ou seus fragmentos e kit | |
BR112017027702A2 (pt) | anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2) | |
BR112023000826A2 (pt) | Anticorpo anti-ctla-4 e uso do mesmo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |